Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus

Coronaviruses raise serious concerns as emerging zoonotic viruses without specific antiviral drugs available. Here we screened a collection of 16671 diverse compounds for anti-human coronavirus 229E activity and identified an inhibitor, designated K22, that specifically targets membrane-bound corona...

Full description

Saved in:
Bibliographic Details
Published inPLoS pathogens Vol. 10; no. 5; p. e1004166
Main Authors Lundin, Anna, Dijkman, Ronald, Bergström, Tomas, Kann, Nina, Adamiak, Beata, Hannoun, Charles, Kindler, Eveline, Jónsdóttir, Hulda R, Muth, Doreen, Kint, Joeri, Forlenza, Maria, Müller, Marcel A, Drosten, Christian, Thiel, Volker, Trybala, Edward
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.05.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Coronaviruses raise serious concerns as emerging zoonotic viruses without specific antiviral drugs available. Here we screened a collection of 16671 diverse compounds for anti-human coronavirus 229E activity and identified an inhibitor, designated K22, that specifically targets membrane-bound coronaviral RNA synthesis. K22 exerts most potent antiviral activity after virus entry during an early step of the viral life cycle. Specifically, the formation of double membrane vesicles (DMVs), a hallmark of coronavirus replication, was greatly impaired upon K22 treatment accompanied by near-complete inhibition of viral RNA synthesis. K22-resistant viruses contained substitutions in non-structural protein 6 (nsp6), a membrane-spanning integral component of the viral replication complex implicated in DMV formation, corroborating that K22 targets membrane bound viral RNA synthesis. Besides K22 resistance, the nsp6 mutants induced a reduced number of DMVs, displayed decreased specific infectivity, while RNA synthesis was not affected. Importantly, K22 inhibits a broad range of coronaviruses, including Middle East respiratory syndrome coronavirus (MERS-CoV), and efficient inhibition was achieved in primary human epithelia cultures representing the entry port of human coronavirus infection. Collectively, this study proposes an evolutionary conserved step in the life cycle of positive-stranded RNA viruses, the recruitment of cellular membranes for viral replication, as vulnerable and, most importantly, druggable target for antiviral intervention. We expect this mode of action to serve as a paradigm for the development of potent antiviral drugs to combat many animal and human virus infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: AL TB CH BA VT ET. Performed the experiments: AL RD EK HRJ JK DM. Analyzed the data: AL BA CH NK ET VT RD EK HRJ DM MAM CD MF. Contributed reagents/materials/analysis tools: NK. Wrote the paper: VT ET RD AL.
JK is employed by a commercial company, Merck Animal Health. This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.
Current address: Avian Viral Diseases Programme, The Pirbright Institute, Compton Laboratory, Compton, United Kingdom
ISSN:1553-7374
1553-7366
1553-7374
DOI:10.1371/journal.ppat.1004166